The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Antengene doses first China patient in Phase I ATG-201 autoimmune study

Nov 6, 2026 00:30 (8h ago)

Verifying

Antengene dosed the first China patient in the Phase I ATTRACT study of ATG-201.
ATG-201 targets CD19-expressing B cells through a CD19 × CD3 bispecific antibody.
Antengene and UCB agreed on worldwide exclusive development, manufacturing and commercialization rights for ATG-201.